GlassScriptPhysician profile
Jason S Alford
NPI 1164048385
$2,792.75
in general payments reported to CMS, 2019-2025
24 companies · $528 in 2025
The $528 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,323 · 2022: $321 · 2023: $188 · 2024: $432 · 2025: $528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,148.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dentsply Sirona INC | $602.50 | 2021 | |
| Patterson Companies, INC. | $602.50 | 2021 | |
| Novartis Pharmaceuticals Corporation | $540.76 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $132.23 | 2022-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $110.73 | 2022 | |
| Ani Pharmaceuticals, INC. | $93.09 | 2022-2025 | Purified Cortrophin Gel |
| Aurinia Pharma U.S., INC. | $88.95 | 2021 | |
| Alexion Pharmaceuticals, INC. | $72.77 | 2022-2024 | Ultomiris |
| Novo Nordisk INC | $65.92 | 2024-2025 | Ozempic, Rivfloza |
| Amgen INC. | $60.15 | 2023-2025 | Tavneos, Aranesp, Parsabiv |
| Travere Therapeutics, INC. | $58.43 | 2025 | |
| Glaxosmithkline, LLC. | $50.16 | 2023-2025 | Benlysta, Jesduvroq |
| Vifor Pharma, INC. | $43.15 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.92 | 2024-2025 | Jardiance |
| Mallinckrodt Hospital Products INC. | $34.97 | 2025 | Terlivaz |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $33.20 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.07 | 2022 | |
| Akebia Therapeutics INC | $26.14 | 2024 | Auryxia, Vafseo |
| Outset Medical INC | $23.66 | 2024 | |
| Baxter Healthcare | $22.10 | 2024 | Renal - Pd |
| Lilly USA, LLC | $17.52 | 2024 | Jardiance |
| Horizon Therapeutics Plc | $17.06 | 2022 | |
| Fresenius USA Marketing, INC. | $16.40 | 2024 | Velphoro |
| Bard Peripheral Vascular, INC. | $16.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Alford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.